Summary
With 20 % of patients responding to their treatment and 10M dying every year, cancer is a recognised societal challenge. While data-driven approaches can double the clinical trials success rate, the pharma industry lacks tools to leverage the large amount of data generated in their drug discovery processes.
We are developing mCUBE, an AI-powered platform that scales precision oncology for drug discovery and repurposing. Best-in-class and user-centric platform, mCUBE encapsulates a cancer-agnostic clinical data harmonisation module with an integrative approach to multi-omic data analysis. As our solution increases in value and allows us to move up the value chain, our initial SaaS business model will progressively switch to a drug discovery model. With mCUBE, we will identify and validate new drug candidates to license IP assets to pharma companies. By 2025, we expect to sign a deal of €25M with a biopharma partner. We will disrupt he oncology market for the benefits of cancer patients.
We are developing mCUBE, an AI-powered platform that scales precision oncology for drug discovery and repurposing. Best-in-class and user-centric platform, mCUBE encapsulates a cancer-agnostic clinical data harmonisation module with an integrative approach to multi-omic data analysis. As our solution increases in value and allows us to move up the value chain, our initial SaaS business model will progressively switch to a drug discovery model. With mCUBE, we will identify and validate new drug candidates to license IP assets to pharma companies. By 2025, we expect to sign a deal of €25M with a biopharma partner. We will disrupt he oncology market for the benefits of cancer patients.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190185351 |
| Start date: | 01-08-2022 |
| End date: | 31-07-2024 |
| Total budget - Public funding: | 3 565 412,50 Euro - 2 495 788,00 Euro |
Cordis data
Original description
With 20 % of patients responding to their treatment and 10M dying every year, cancer is a recognised societal challenge. While data-driven approaches can double the clinical trials success rate, the pharma industry lacks tools to leverage the large amount of data generated in their drug discovery processes.We are developing mCUBE, an AI-powered platform that scales precision oncology for drug discovery and repurposing. Best-in-class and user-centric platform, mCUBE encapsulates a cancer-agnostic clinical data harmonisation module with an integrative approach to multi-omic data analysis. As our solution increases in value and allows us to move up the value chain, our initial SaaS business model will progressively switch to a drug discovery model. With mCUBE, we will identify and validate new drug candidates to license IP assets to pharma companies. By 2025, we expect to sign a deal of €25M with a biopharma partner. We will disrupt he oncology market for the benefits of cancer patients.
Status
SIGNEDCall topic
HORIZON-EIC-2021-ACCELERATOROPEN-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
